menu
    • menu

    Company profile for Kazia Therapeutics

    NEW Drugs in Dev: 5
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kazia is a new company, with great potential in its pipeline, a clear strategy to realise value for shareholders, and a lean team with the experience and expertise to deliver benefit to patients. Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is a biotechnology company developing innovative drugs for the treatment of a range of cancers with significant unmet medical need. It is based in Sydney, Australia. Our lead program...
    Kazia is a new company, with great potential in its pipeline, a clear strategy to realise value for shareholders, and a lean team with the experience and expertise to deliver benefit to patients. Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is a biotechnology company developing innovative drugs for the treatment of a range of cancers with significant unmet medical need. It is based in Sydney, Australia. Our lead program, GDC-0084, is being developed to treat aggressive brain cancer (glioblastoma multiforme [GBM]).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kazia TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    300 Barangaroo Ave L24 Barangaroo, New South Wales 2000
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kaziatherapeutics.com/site/content/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kaziatx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KaziaTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia's Nuclear PD-L1 Degrader: Preclinical & Translational Data
    Kazia's Nuclear PD-L1 Degrader: Preclinical & Translational Data

    30 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2-302674710.html

    PR NEWSWIRE BIO
    30 Jan 2026
    Share Share
    Kazia Shows Positive Early Results In Phase 1B Paxalisib Study
    Kazia Shows Positive Early Results In Phase 1B Paxalisib Study

    27 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer-302670593.html

    PR NEWSWIRE
    27 Jan 2026
    Share Share
    Kazia Pharma Joins J.P. Morgan Healthcare Conference
    Kazia Pharma Joins J.P. Morgan Healthcare Conference

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-to-participate-in-jp-morgan-healthcare-conference-week-clinical-and-translational-update-anticipated-before-month-end-302656513.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    Kazia Therapeutics Regains Full Nasdaq Listing Compliance
    Kazia Therapeutics Regains Full Nasdaq Listing Compliance

    22 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/kazia-therapeutics-regains-full-nasdaq-listing-compliance-302647695.html

    PR NEWSWIRE BIO
    22 Dec 2025
    Share Share
    Kazia Pharma Showcases Paxalisib's Anti-Tumor Immunity Boost
    Kazia Pharma Showcases Paxalisib's Anti-Tumor Immunity Boost

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-highlights-new-clinical-and-translational-findings-demonstrating-paxalisibs-ability-to-reinvigorate-anti-tumor-immunity-across-multiple-advanced-breast-cancer-populations-including-tnbc-and-her2-302637493.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Kazia Pharma Prices $50M Private Placement
    Kazia Pharma Prices $50M Private Placement

    02 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-pricing-of-50-0-million-private-placement-of-equity-securities-302630502.html

    PR NEWSWIRE
    02 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search